Life Science Investing Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
Life Science Investing Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data
Life Science Investing Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Life Science Investing Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, "NEO-CYT", in High-Risk, Surgically Resectable Stage III Melanoma
Life Science Investing Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology Immuno-Oncology Congress 2025
Life Science Investing ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City
Life Science Investing Medicenna Therapeutics to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
Life Science Investing Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
